Found 25 articles for: "Crisaborole"
Chronic Nasolabial Fold Seborrheic Dermatitis Successfully Controlled With Crisaborole
May 2018 | Volume 17 | Issue 5 | Editorials | 577 | Copyright © May 2018
Chronic Nasolabial Fold Seborrheic Dermatitis Successfully Controlled With Read More
Trends in Atopic Dermatitis Management: Comparison of 1990-1997 to 2003-2012
February 2018 | Volume 17 | Issue 2 | Original Article | 135 | Copyright © February 2018
BACKGROUND: Atopic dermatitis (AD) is primarily treated with topical therapies, systemic immunosuppressants, or adjunctive therapies. OBJECTIVE: As novel treatment approaches for AD emerge, we charac...
Read MoreThe Latest Drugs and Small Molecule Inhibitors for Skin and Hair
December 2017 | Volume 16 | Issue 12 | Original Article | 1224 | Copyright © December 2017
Biologic drugs, a novel class of agents engineered to target specifc mediators of infammation, and small-molecule inhibitors that pen-etrate the cell membrane to interact with targets inside a cell...
Read MoreA Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis
December 2015 | Volume 14 | Issue 12 | Original Article | 1394 | Copyright © December 2015
BACKGROUND: Crisaborole is a novel, boron-based, small-molecule, topical phosphodiesterase-4 inhibitor in development for the treatment of patients with mild to moderate atopic dermatitis (AD).
M...
Read MoreCrisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study
October 2015 | Volume 14 | Issue 10 | Original Article | 1108 | Copyright © October 2015
BACKGROUND: A novel approach for treating atopic dermatitis (AD) is the inhibition of phosphodiesterase 4 (PDE4), an enzyme involved in the proinflammatory cascade. Crisaborole topical ointment, 2% is...
Read More